NCT00076011View on ClinicalTrials.gov

Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
Kidney Neoplasms
Interventions
DRUG

Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor

Trial Locations (9)

10021

Pfizer Investigational Site, New York

30625

Pfizer Investigational Site, Hanover

44195

Pfizer Investigational Site, Cleveland

53792

Pfizer Investigational Site, Madison

75651

Pfizer Investigational Site, Paris

94115

Pfizer Investigational Site, San Francisco

02114

Pfizer Investigational Site, Boston

02115

Pfizer Investigational Site, Boston

19111-2497

Pfizer Investigational Site, Philadelphia

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY